2026-01-18 - Analysis Report
**MRK Merck & Co Inc Report**

### Company Overview
Merck & Co Inc, a global healthcare company involved in the research, development, and commercialization of various medicines and vaccines.

### Return Comparison and Divergence
#### Return Comparison
- Review Stock (MRK): 25.67%
- Comparison Stock (VOO): 93.36%
- **Divergence**: -68.69%

#### Alpha, Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | 24.0% | 14.7% | 21.0% | 0.7  | 182.1B |
| 2017-2019  | 37.0% | 14.7% | 20.0% | 0.7  | 216.8B |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7  | 195.0B |
| 2019-2021  | 0.0% | 19.3% | -43.0% | 0.6  | 191.4B |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5  | 277.1B |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3  | 272.3B |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3  | 248.5B |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3  | 262.9B |

### Stock Price Fluctuations
- Recent Close: $108.83
- Recent 5-day SMA: $109.65
- Recent 20-day SMA: $107.19
- Recent 60-day SMA: $98.44

### Indicators Analysis
- Market Risk Indicator (MRI): 0.80
  * High Investment Recommended: 0.9~1.0
  * Medium Investment: 0.7~0.9
  * Low Investment: 0.4~0.7
  * Very Risky: <0.4
- RSI: 56.63
- PPO: -0.18
- Expected Return: -26.70%
- Recent relative divergence change: -0.70 (-)
- 7-day Rank change: -58 (-)
- 7-day Dynamic Expected Return change: 0.00 (0)

### News and Significant Events
- [2026-01-15] What’s In Store For Merck Stock? - Trefis
- [2026-01-15] Is Merck Stock A Trap At $110? - Forbes
- [2026-01-17] Merck & Co., Inc. $MRK Shares Sold by QRG Capital Management Inc. - MarketBeat
- [2026-01-14] Is Merck KGaA (XTRA:MRK) Share Price Misaligned With Cash Flow And Earnings Valuation Estimates - Yahoo Finance
- [2026-01-16] Is Merck (MRK) Pricing In Its Recent Share Run Or Leaving Further Upside? - simplywall.st
- [2026-01-17] Merck stock price slips after FDA fast-track questions; what MRK investors watch next week - TechStock²

### Analyst Opinions
 Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 113.48 / 135.00 / 83.00

### Recent Earnings Analysis
| Date | EPS | Revenue |
| ---:|---:|---:|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

### Financial Information (Revenue and Profitability)
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

### Financial Information (Capital and Profitability)
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

### Comprehensive Analysis (Summary)
- Review stock returns (MRK) show significant divergence from S&P 500 (VOO).
- Alpha, Beta analysis reveals variable performance over the years.
- Stock price fluctuations (5-day, 20-day, 60-day SMA) indicate a possible downtrend.
- Indicator analysis (MRI, RSI, PPO) suggests a medium investment risk.
- Recent news and significant events show various perspectives on the company.
- Analyst opinions suggest a buy recommendation, with a target price range.
- Recent earnings analysis shows varying EPS and revenue growth.
- Financial information (Revenue and Profitability, Capital and Profitability) indicates strong revenue margins and equity growth.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.